Canonical Wnt signaling in systemic sclerosis

Laboratory Investigation

Volumn 96, Issue 2, 2016, Pages 151-155

  Bergmann, Christina ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; ANTIFIBROTIC AGENT; BETA CATENIN; DICKKOPF 1 PROTEIN; DNA METHYLTRANSFERASE; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; PKF 118 310; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; WNT10B PROTEIN; WNT3A PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CELL ACTIVATION; DISEASE ASSOCIATION; EXPERIMENTAL FIBROSIS; GENE OVEREXPRESSION; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; WNT SIGNALING PATHWAY; HUMAN;

HUMANS; SCLERODERMA, SYSTEMIC; WNT SIGNALING PATHWAY;

EID: 84955603885     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.154     Document Type: Article

References (39)

1. Gurtner GC, Werner S, Barrandon Y et al. Wound repair and regeneration. Nature 2008;453:314-321.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-567.
3. Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 2014;26:131-137.
4. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
5. Ramming A, Dees C, Distler JH. From pathogenesis to therapy-Perspective on treatment strategies in fibrotic diseases. Pharmacol Res 2015;100:93-100.
6. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972;135:1351-1362.
7. Akhmetshina A, Palumbo K, Dees C et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012;3:735.
8. Beyer C, Schramm A, Akhmetshina A et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012;71:761-767.
9. Reich N, Tomcik M, Zerr P et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012;71:737-745.
10. Bergmann C, Akhmetshina A, Dees C et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011;70:2191-2198.
11. He W, Dai C, Li Y et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009;20:765-776.
12. Konigshoff M, Kramer M, Balsara N et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009;119:772-787.
13. Kobayashi K, Luo M, Zhang Y et al. Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol 2009;11:46-55.
14. Dees C, Tomcik M, Zerr P et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011;70:1304-1310.
15. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 2012;31:2670-2684.
16. Nusse R. Wnt signaling. Cold Spring Harb Perspect Biol 2012;4:5.
17. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
18. Gao Z, Xu Z, Hung MS et al. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep 2009;22:1479-1484.
19. Wang X, Wang H, Bu R et al. Methylation and aberrant expression of the Wnt antagonist secreted Frizzled-related protein 1 in bladder cancer. Oncol Lett 2012;4:334-338.
20. Dees C, Schlottmann I, Funke R et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014;73:1232-1239.
21. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012;149:1192-1205.
22. Hao HX, Xie Y, Zhang Y et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012;485:195-200.
23. Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-620.
24. Svegliati S, Marrone G, Pezone A et al. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal 2014;7:ra84.
25. Lam AP, Flozak AS, Russell S et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol 2011;45:915-922.
26. Ulsamer A, Wei Y, Kim KK et al. Axin pathway activity regulates in vivo pY654-beta-catenin accumulation and pulmonary fibrosis. J Biol Chem 2012;287:5164-5172.
27. Hamburg EJ, Atit RP. Sustained beta-catenin activity in dermal fibroblasts is sufficient for skin fibrosis. J Invest Dermatol 2012;132: 2469-2472.
28. Hamburg-Shields E, DiNuoscio GJ, Mullin NK et al. Sustained beta-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes. J Pathol 2015;235:686-697.
29. Ren S, Johnson BG, Kida Y et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA 2013;110: 1440-1445.
30. Wei J, Fang F, Lam AP et al. Wnt/beta-catenin signaling is hyper-activated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012;64:2734-2745.
31. Distler A, Ziemer C, Beyer C et al. Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Ann Rheum Dis 2014;73: 624-627.
32. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov 2014;13:513-532.
33. Beyer C, Reichert H, Akan H et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013;72: 1255-1258.
34. Henderson Jr WR, Chi EY, Ye X et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 2010;107:14309-14314.
35. Hao S, He W, Li Y et al. Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011;22:1642-1653.
36. Distler A, Deloch L, Huang J et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis 2013;72:1575-1580.
37. Pinto D, Gregorieff A, Begthel H et al. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev 2003;17:1709-1713.
38. Kuhnert F, Davis CR, Wang HT et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci USA 2004;101: 266-271.
39. Distler A, Lang V, Del Vecchio T et al. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis 2014;73:1264-1268.